12th Annual Women and Ischemic Heart Disease Symposium

12th Annual Women and Ischemic Heart Disease Symposium is organized by Cedars-Sinai Medical Center and will be held on May 11, 2018 at Cedars Sinai Medical Center Harvey Morse Conference Center South Tower, Los Angeles, California, United States of America.

The target audience for this medical event is physicians, surgeons and other healthcare professionals. This CME Conference has been approved for a maximum of 7.0 AMA PRA Category 1 Credits.

Conference Description:
Cardiovascular disease (CVD) was once thought of as primarily affecting men, but today, CVD is the number one killer of women in the US, claiming almost 400,000 American women every year. Furthermore, as the average age of the American woman increases, the morbidity and mortality rates of CVD are likely to increase dramatically.

Yet, many women at risk for coronary heart disease are often not referred for appropriate diagnostic testing, perhaps because until recently, it was thought that the clinical manifestations of women with cardiovascular disease were essentially similar to those of men and warranted similar management. This means the disease process resulting in a heart attack or stroke may not be detected in women until later, with more serious consequences. Despite significant advances in our knowledge about preventive interventions, cardiovascular disease remains the leading killer of women in the United States. In an effort to further education in this area our planning committee has assembled a distinguished faculty of national speakers, each with a unique expertise in the field of cardiovascular health and heart disease.

This in-depth educational symposium will explore gender-specific issues in coronary microvascular dysfunction, hormone therapy, cardiac resynchronization therapy, and updates in research and health policy. The purpose of this conference is to close the knowledge gap of physicians and allied healthcare professionals regarding sex-specific differences in cardiovascular disease, the impact these differences have on treatment options, and to highlight the importance of identifying women at risk for cardiovascular disease by utilizing the most current evidence-based treatment strategies for improved patient outcomes.

Conference Objectives:
• Examine the improvement of medical product development, product safety and efficacy in women from a regulatory perspective.
• Discuss how to advise women on reproductive hormone therapy and cardiac risk.
• Relate the benefits of referring women with heart disease to a cardiac rehabilitation program.
• Review and understand the impact of supplements and fish oil on cholesterol.
• Analyze the benefits of using cardiac resynchronization therapy in women with heart failure with preserved ejection fraction.
• Describe anatomical valve disease amenable to percutaneous therapies.
• Assess the risks and benefits of percutaneous therapies.
• Describe how clinical manifestations of cardiovascular disease vary in women.
• Evaluate appropriate diagnostic testing for coronary microvascular dysfunction in women with chest pain who do not have obstructive coronary artery disease.
• Define the role of specialized care teams focused on Women’s Heart Health and Disease.
• Explore case examples of hormone, stress, cholesterol, hypertension and CMD management and interventions.
• Focus clinical practice approach on the unique aspects of cardiovascular care for women to provide necessary resources for prevention, diagnosis, and treatment of CVD in women.

Additional details will be posted as soon as they are available.